Aktis Oncology (AKTS)
Develops targeted radiopharmaceuticals for solid tumors using miniprotein radioconjugates.
$21.04
vs last close−1.07 (−4.84%)
In millions of USD, except per-share figures
| In millions | Q4 FY24Dec 2024 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1 | 2 | 2 | 3 | 3 |
| Cost of revenue | 0 | 0 | 0 | 1 | 1 |
| Gross profit | 1 | 2 | 2 | 3 | 3 |
| 17 | 20 | 19 | 25 | 31 | |
| Research & development | 13 | 16 | 16 | 20 | 25 |
| 4 | 3 | 3 | 5 | 6 | |
| General & administrative | 4 | 3 | 3 | 0 | 0 |
| Other expenses | 0 | 0 | 0 | 0 | 0 |
| Operating income | −16 | −18 | −17 | −23 | −29 |
| 4 | 3 | 2 | 4 | 5 | |
| Interest income | 4 | 3 | 2 | 4 | 5 |
| Other non-operating income | −4 | 0 | −2 | −4 | 0 |
| Income before tax | −12 | −16 | −15 | −18 | −24 |
| Net income from continuing operations | −12 | −16 | −15 | −18 | −24 |
| Net income | −12 | −16 | −15 | −18 | −24 |
| EPS, basic | −$0.23 | $0.00 | −$0.28 | −$0.33 | −$0.44 |
| EPS, diluted | −$0.23 | $0.00 | −$0.28 | −$0.33 | −$0.44 |
| Weighted average shares, basic | 53 | 0 | 53 | 55 | 55 |
| Weighted average shares, diluted | 53 | 0 | 53 | 55 | 55 |
| EBITDA | −12 | −18 | −14 | −18 | −28 |
| Depreciation & amortization | 0 | 1 | 1 | 1 | 1 |
| EBIT | −12 | −18 | −15 | −18 | −29 |